# JumpCode Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jumpcode-genomics

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.jumpcodegenomics.com
- Total disclosed funding: $21M
- Latest round: Series B (Dec 18, 2020)
- Investors on record: 3

## About

JumpCode Genomics focuses on advanced genomic analysis tools, enhancing sensitivity and specificity in next-generation sequencing applications to support diverse research needs across various scientific disciplines.JumpCode Genomics, Inc. was founded in 2016 and specializes in developing innovative genomic analysis tools. The company is headquartered in Carlsbad, US. Keith Brown is noted as the founder, while Mike Salter serves as the CEO. JumpCode has successfully executed 3 deals, with the most recent being a Series B round of funding on December 18, 2020, amounting to USD 21.00 mn, co-led by Arboretum Ventures and Baird Capital Partners, along with participation from LYZZ Capital.JumpCode Genomics specializes in advanced genomic analysis tools designed to enhance the sensitivity and specificity of next-generation sequencing (NGS) applications. Their core offerings, including the DepleteX™ and CRISPRclean™ kits, address common challenges in genomic research by depleting undesired fragments from NGS libraries. This allows researchers to gain clearer insights into individual cell expression profiles, characterize microbial populations, and detect pathogens, thereby improving outbreak investigations and overall genomic discovery. The products are utilized across various applications, including single-cell analysis, microbiome research, infectious disease surveillance, and agrigenomics, serving a diverse clientele that includes academic institutions, healthcare organizations, and research laboratories worldwide. They have a presence in key markets such as North America, Europe, and Asia, positioning themselves as leaders in the genomics field.JumpCode Genomics generates revenue primarily through the sales of its trademarked products, including the DepleteX™ and CRISPRclean™ kits, which are crucial for genomic applications. The company operates on a B2B model, selling directly to research institutions and commercial laboratories that utilize these tools for their genomic studies. Transactions typically involve bulk orders, where clients purchase kits tailored to specific applications or research needs, often resulting in long-term partnerships. As a result, JumpCode Genomics facilitates ongoing relationships with its customers through repeat purchases and custom depletion panel designs, which can be developed to target a wide range of genomic sequences, from one to over a million targets. This transactional framework ensures a steady revenue stream as the demand for precise genomic analysis continues to grow.JumpCode Genomics aims to enhance its product lineup with upcoming offerings designed for more specific applications in genomic analysis. The company has plans to expand into the European and Asian markets by the end of 2022. The recent Series B funding of USD 21.00 mn will be utilized to support these initiatives, particularly in accelerating product development and market penetration strategies.

## Funding rounds

- Series B, Dec 18, 2020, $21M — Baird Capital Partners, Arboretum Ventures, LYZZ Capital

## Investors

- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series B
- LYZZ Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B